Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.

Carbonell D, Suárez-González J, Chicano M, Andrés-Zayas C, Triviño JC, Rodríguez-Macías G, Bastos-Oreiro M, Font P, Ballesteros M, Muñiz P, Balsalobre P, Kwon M, Anguita J, Díez-Martín JL, Buño I, Martínez-Laperche C.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1364. doi: 10.3390/cancers11091364.

2.

Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?

Font P, Subirá D, Matarraz S, Benavente C, Cedena MT, Morado M, Pérez Corral A, Bellón JM, Díez-Martín JL.

Cytometry B Clin Cytom. 2018 May;94(3):527-535. doi: 10.1002/cyto.b.21538. Epub 2017 Jul 6.

3.

Myelodysplastic syndrome after breast cancer. The challenge of late complications in long-term survivors.

Font P.

Leuk Res. 2016 Oct;49:88-9. doi: 10.1016/j.leukres.2016.08.010. Epub 2016 Aug 24. No abstract available.

PMID:
27614247
4.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
5.

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.

Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martín-Clavero E, López-Rubio M, Garcia-Alonso L, Callejas M, Bermejo A, Benavente C, Ballesteros M, Cedena T, Calbacho M, Urbina R, Villarrubia J, Gil S, Bellón JM, Diez-Martin JL, Villegas A.

Ann Hematol. 2015 Apr;94(4):565-73. doi: 10.1007/s00277-014-2252-4. Epub 2014 Nov 13.

PMID:
25387664
6.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
7.

Acute myeloblastic leukemia.

Molina CA, Rodríguez MJ, de Marcos NS, Font P.

Adv Ther. 2011 Mar;28 Suppl 3:10-6. doi: 10.1007/s12325-010-0109-3. Epub 2011 Mar 9.

PMID:
21431629
8.

Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.

Font P.

Adv Ther. 2011 Mar;28 Suppl 3:1-9. doi: 10.1007/s12325-011-0002-8. Epub 2011 Mar 9. Review.

PMID:
21431628
9.

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM.

Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22.

10.

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.

Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.

Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

11.

Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?

Subirá D, Font P, Villalón L, Serrano C, Askari E, Góngora E, Castañón S, Gonzalo R, Mata R, Román A, Llamas P.

Transl Res. 2008 May;151(5):240-5. doi: 10.1016/j.trsl.2008.03.001. Epub 2008 Apr 7.

PMID:
18433705
12.

Expression of CD7 in myelodysplastic syndromes (MDS): is this a truly prognostic factor?

Font P, Subirá D.

Leuk Res. 2008 Jan;32(1):185-6. Epub 2007 Mar 26. No abstract available.

PMID:
17383724

Supplemental Content

Loading ...
Support Center